Target Market

Our target market encompasses a wide spectrum of stakeholders within the healthcare industry, including healthcare providers, diagnostic laboratories, research institutions, and public health agencies. Additionally, our solutions are designed to address the needs of diverse patient populations, spanning across various demographic and geographic settings. While initially focusing on specific diseases such as dengue fever, our vision extends to addressing a broader range of health- care challenges on a global scale.

Revenue Model

1.Poduct Sales
Diagnostic Kits: FIDIANT generates revenue through the sale of our proprietary diagnostic kits, including the Dengue Specific Nano Biosensor Kit and future offerings targeting other infectious diseases. These kits are sold to healthcare providers, diagnostic laboratories, research Institutions, and public health agencies.

2.Services
Training and Support: FIDIANT provides training and support services to our customers to ensure proper utilization and maintenance of our diagnostic platforms. This may include onsite training, virtual training sessions, technical assistance, and troubleshooting support..

Value Proposition

Cost Savings: Our nanotechnology-driven diagnostic platforms are designed to be cost-effective and efficient, helping healthcare systems save resources and reduce healthcare costs. By enabling early detection and prevention of diseases, our solutions mitigate the need for expensive treatments and hospitalizations, resulting in significant cost savings for healthcare providers and payers.

Innovation and Differentiation: FIDIANT's commitment to innovation and technological advancement sets us apart in the healthcare diagnostics landscape. Our nanotechnology-driven platforms offer unparalleled sensitivity, speed, and reliability, providing healthcare providers with cutting-edge tools to address complex diagnostic challenges and stay ahead of emerging health threats.

Market Strategy

1.research

2.Planning

3.Team Work

4.Strategy

5.Target

6.Growth

7.Vision

Fidiant Private Limited was established in 2023 by Dr. Kishor Kumar C, Ph.D. in Medicinal Chemistry, from University of Mysore,b Karnataka India. Having 18+ years of Industrial experience. Before this he was a Founder and Managing Director of Bioben that was established in 2012. Bioben was a technology & product development company, catering to the changing needs of the life science, veterinary, dairy science industries and education institutes. Bioben was registered as a partnership firm now the company is converted into a Private Limited Company in the name of 'Fidiant Private Limited' because, a partnership firm in India has no separate legal status separate from its partners. However, a Private Limited Company is an artificial separate legal entity and can hold assets and incur liability in its names and registered under the Indian Companies Act, 1956 or any other previous act.